Search results
Results From The WOW.Com Content Network
Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. ... or any type of positive result on either a urine or blood ...
The M2-PK Test is a non-invasive screening method for the early detection of colorectal cancers and polyps which are known to be the precursors of colorectal cancer. The M2-PK Test which is used for stool analysis is available either as fully quantitative ELISA Test or as a rapid test that can be performed by any general practitioner without the need of a laboratory or any additional equipment.
Cologuard refers to an at-home stool DNA test that can help screen for colon cancer or polyps.A person enrolled in Medicare aged between 45 and 85 is eligible for coverage for a Cologuard test ...
Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer.
Fecal occult blood test is no longer recommended due to the high false-positive rate as well as the dietary and pharmaceutical restrictions. [5] [6] The National Committee for Quality Assurance (NCQA) issued an update to the Healthcare Effectiveness Data and Information Set (HEDIS) for 2017, while the guideline remains for the patients aged 50 ...
The company said it plans to complete submission of its marketing application for the new test to the U.S. Food and Drug Administration (FDA) by the end of this year. The company reported $1.43 ...
Fecal occult blood testing (FOBT), as its name implies, aims to detect subtle blood loss in the gastrointestinal tract, anywhere from the mouth to the colon.Positive tests ("positive stool") may result from either upper gastrointestinal bleeding or lower gastrointestinal bleeding and warrant further investigation for peptic ulcers or a malignancy (such as colorectal cancer or gastric cancer).
An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback.